World News

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Chairman Sells $392,625.00 in Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Chairman Sells 2,625.00 in Stock

Vertex Prescription drugs Integrated (NASDAQ:VRTX – Get Score) Chairman Jeffrey M. Leiden bought 1,125 shares of the enterprise’s inventory in a transaction dated Monday, Could eighth. The inventory was bought at a mean worth of $349.00, for a complete transaction of $392,625.00. Following the completion of the sale, the chairman now owns 35,387 shares within the firm, valued at $12,350,063. The transaction was disclosed in a authorized submitting with the SEC, which might be accessed by way of this hyperlink.

Vertex Prescription drugs Worth Efficiency

Shares of Vertex Prescription drugs inventory opened at $350.04 on Thursday. The corporate has a debt-to-equity ratio of 0.03, a present ratio of 4.28 and a fast ratio of 4.11. The enterprise’s 50 day easy shifting common is $317.96 and its two-hundred day easy shifting common is $308.81. The inventory has a market capitalization of $90.15 billion, a P/E ratio of 27.87, a price-to-earnings-growth ratio of three.23 and a beta of 0.49. Vertex Prescription drugs Integrated has a one 12 months low of $233.01 and a one 12 months excessive of $354.46.

Vertex Prescription drugs (NASDAQ:VRTX – Get Score) final launched its earnings outcomes on Monday, Could 1st. The pharmaceutical firm reported $3.05 EPS for the quarter, topping analysts’ consensus estimates of $2.51 by $0.54. Vertex Prescription drugs had a return on fairness of 25.06% and a web margin of 35.40%. The agency had income of $2.37 billion for the quarter, in comparison with analysts’ expectations of $2.34 billion. Throughout the identical interval within the prior 12 months, the agency posted $3.16 earnings per share. The corporate’s quarterly income was up 13.2% on a year-over-year foundation. Analysts forecast that Vertex Prescription drugs Integrated will submit 12.99 EPS for the present 12 months.

Hedge Funds Weigh In On Vertex Prescription drugs

Institutional buyers have just lately added to or lowered their stakes within the firm. Sandy Spring Financial institution raised its place in Vertex Prescription drugs by 1,014.3% throughout the 1st quarter. Sandy Spring Financial institution now owns 78 shares of the pharmaceutical firm’s inventory valued at $25,000 after buying a further 71 shares within the final quarter. Y.D. Extra Investments Ltd bought a brand new stake in shares of Vertex Prescription drugs within the fourth quarter value about $26,000. Steward Monetary Group LLC bought a brand new stake in shares of Vertex Prescription drugs within the fourth quarter value about $28,000. Outdated North State Belief LLC acquired a brand new place in Vertex Prescription drugs within the third quarter value about $29,000. Lastly, New Hampshire Belief acquired a brand new place in Vertex Prescription drugs within the 4th quarter value about $29,000. Hedge funds and different institutional buyers personal 90.96% of the corporate’s inventory.

Analyst Rankings Modifications

A variety of analysis corporations just lately commented on VRTX. Stifel Nicolaus elevated their goal worth on shares of Vertex Prescription drugs from $300.00 to $340.00 in a analysis report on Tuesday, Could 2nd. Maxim Group lifted their goal worth on shares of Vertex Prescription drugs from $325.00 to $400.00 in a analysis word on Wednesday, Could third. Robert W. Baird lifted their worth goal on shares of Vertex Prescription drugs from $280.00 to $325.00 in a analysis report on Tuesday, Could 2nd. SVB Securities dropped their worth goal on shares of Vertex Prescription drugs from $374.00 to $365.00 in a report on Wednesday, February eighth. Lastly, SVB Leerink lowered their worth goal on shares of Vertex Prescription drugs from $374.00 to $365.00 and set an “outperform” score for the corporate in a analysis report on Wednesday, February eighth. 5 equities analysis analysts have rated the inventory with a maintain score, ten have assigned a purchase score and one has issued a powerful purchase score to the corporate’s inventory. In accordance with MarketBeat.com, the inventory presently has a consensus score of “Average Purchase” and a consensus worth goal of $352.59.

About Vertex Prescription drugs

(Get Score)

Vertex Prescription drugs, Inc is a worldwide biotechnology firm, which engages within the enterprise of discovering, growing, manufacturing, and commercializing small molecule medication for sufferers with critical illnesses. The agency focuses on growth and commercializing therapies for the remedy of cystic fibrosis, infectious illnesses together with viral infections resembling influenza and bacterial infections, autoimmune illnesses resembling rheumatoid arthritis, most cancers, inflammatory bowel illness and neurological problems together with ache and a number of sclerosis.

Learn Extra

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)



Obtain Information & Rankings for Vertex Prescription drugs Every day – Enter your e-mail deal with beneath to obtain a concise each day abstract of the most recent information and analysts’ rankings for Vertex Prescription drugs and associated corporations with MarketBeat.com’s FREE each day e-mail publication.

Inflation, COVID Plunge 68 Million More In Asia Into Extreme Poverty: Asian Development Bank

Mugen

Full test of communique from 12th AIGF 2023 hosted by NCC

Mugen

Delta Air Lines, Inc. (NYSE:DAL) Shares Purchased by Perigon Wealth Management LLC

Mugen
dnka xsnl mcpa csnl